Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical research policy, take two

This article was originally published in The Gray Sheet

Executive Summary

Both federally funded and private trials would be affected by CMS's latest 1proposal to clarify its coverage of "usual patient care" for beneficiaries participating in clinical studies. Unlike the current policy, the proposal allows study sponsors and principle investigators to self-certify that their studies meet agency criteria in order to receive coverage. Standards require registration on ClinicalTrials.gov, public release of study results within two years after the end of data collection, and discussion of how results are or are not expected to generalize to the Medicare population. CMS issued the proposal July 19. It addresses "confusion and ambiguity" that became apparent after the agency first proposed a revision to the original policy in April (2"The Gray Sheet" July 16, 2007, p. 8). Comments on the new proposal are due Aug. 18, and CMS hopes to finalize the policy in October...

You may also be interested in...



CMS Sticks To Status Quo On Clinical Research Coverage, For Now

Major revisions to CMS' policy on covering clinical research costs were put on hold July 9 in response to stakeholder demands for more input

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel